Reply - 24/04/13
, Bruno Sassolas, MD d, Jean Claude Roujeau, MD e, Maja Mockenhaupt, MD a| Supported by the following institutions/companies for the funding of the EuroSCAR project (unrestricted grants): ADIR & Cie, Bayer Pharma/AG/Vital, Boehringer Ingelheim, Cassenne, Ciba Geigy/Novartis, Cilag GmbH, Dr. Willmar Schwabe, Goedecke Parke Davis, Glaxo Wellcome/GlaxoSmithKline, Hoechst AG/Hoechst Marion Roussel/Aventis, Hoffmann-La-Roche, IRIS Servier, Jouveinal Lab., LEO, LILLY, MSD Sharp & Dohme, Pfizer, Rhone Poulenc Rorer, Sanofi Winthrop/Sanofi Synthelabo GmbH, and Schering AG. Funding from Pharmaceutical Companies in France was managed through contract with INSERM (Institut National de la Santé et de la Recherche Médicale), the French Ministry of Health (PHRC AOM 98027), and GIS-Institut des Maladies Rares. |
|
| Conflicts of interest: None declared. |
Vol 59 - N° 5
P. 899-900 - novembre 2008 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?
